135 related articles for article (PubMed ID: 23435463)
41. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.
Dvorakova D; Racil Z; Jeziskova I; Palasek I; Protivankova M; Lengerova M; Razga F; Mayer J
Am J Hematol; 2010 Dec; 85(12):926-9. PubMed ID: 20981679
[TBL] [Abstract][Full Text] [Related]
42. Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.
Garcia JS; Huang M; Medeiros BC; Mitchell BS
Clin Cancer Res; 2016 Apr; 22(8):1978-88. PubMed ID: 26634271
[TBL] [Abstract][Full Text] [Related]
43. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
Falini B
Cancer Treat Res; 2010; 145():149-68. PubMed ID: 20306250
[TBL] [Abstract][Full Text] [Related]
44. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.
Duek A; Lundberg P; Shimizu T; Grisouard J; Karow A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC
Blood; 2014 Jun; 123(25):3943-50. PubMed ID: 24820309
[TBL] [Abstract][Full Text] [Related]
45. Nucleophosmin Mutants Promote Adhesion, Migration and Invasion of Human Leukemia THP-1 Cells through MMPs Up-regulation via Ras/ERK MAPK Signaling.
Xian J; Shao H; Chen X; Zhang S; Quan J; Zou Q; Jin H; Zhang L
Int J Biol Sci; 2016; 12(2):144-55. PubMed ID: 26884713
[TBL] [Abstract][Full Text] [Related]
46. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
[TBL] [Abstract][Full Text] [Related]
47. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
48. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.
Mason EF; Hasserjian RP; Aggarwal N; Seegmiller AC; Pozdnyakova O
Blood Adv; 2019 Nov; 3(21):3322-3332. PubMed ID: 31698462
[TBL] [Abstract][Full Text] [Related]
49. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.
Falini B; Sportoletti P; Martelli MP
Curr Opin Oncol; 2009 Nov; 21(6):573-81. PubMed ID: 19770764
[TBL] [Abstract][Full Text] [Related]
50. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
Falini B; Martelli MP; Mecucci C; Liso A; Bolli N; Bigerna B; Pucciarini A; Pileri S; Meloni G; Martelli MF; Haferlach T; Schnittger S
Haematologica; 2008 May; 93(5):775-9. PubMed ID: 18367491
[TBL] [Abstract][Full Text] [Related]
51.
Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
Turk J Haematol; 2018 Mar; 35(1):49-53. PubMed ID: 29129825
[TBL] [Abstract][Full Text] [Related]
52. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
[TBL] [Abstract][Full Text] [Related]
53. Nucleophosmin mutation analysis in acute myeloid leukaemia: Immunohistochemistry as a surrogate for molecular techniques.
Chopra A; Soni S; Pati H; Kumar D; Diwedi R; Verma D; Vishwakama G; Bakhshi S; Kumar S; Gogia A; Kumar R
Indian J Med Res; 2016 Jun; 143(6):763-768. PubMed ID: 27748301
[TBL] [Abstract][Full Text] [Related]
54. Effect of NPM1 type B mutation on the proliferation, invasion and chemosensitivity of THP-1 leukemia cells.
Peng J; Fu B; Fu G; Zhao X; Li X; Chen F
Pharmazie; 2017 Oct; 72(10):608-613. PubMed ID: 29441887
[TBL] [Abstract][Full Text] [Related]
55. New insights into the biology of acute myeloid leukemia with mutated NPM1.
Brunetti L; Gundry MC; Goodell MA
Int J Hematol; 2019 Aug; 110(2):150-160. PubMed ID: 30632059
[TBL] [Abstract][Full Text] [Related]
56. MicroRNA expression in maturing murine megakaryocytes.
Opalinska JB; Bersenev A; Zhang Z; Schmaier AA; Choi J; Yao Y; D'Souza J; Tong W; Weiss MJ
Blood; 2010 Dec; 116(23):e128-38. PubMed ID: 20720187
[TBL] [Abstract][Full Text] [Related]
57. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
58. Rapid and highly specific screening for NPM1 mutations in acute myeloid leukemia.
Oppliger Leibundgut E; Porret NA; Bienz Muggli M; Baumgartner H; Dahlhaus M; Baerlocher GM
Ann Hematol; 2013 Jan; 92(2):173-7. PubMed ID: 23161387
[TBL] [Abstract][Full Text] [Related]
59. miR-181a promotes G1/S transition and cell proliferation in pediatric acute myeloid leukemia by targeting ATM.
Liu X; Liao W; Peng H; Luo X; Luo Z; Jiang H; Xu L
J Cancer Res Clin Oncol; 2016 Jan; 142(1):77-87. PubMed ID: 26113450
[TBL] [Abstract][Full Text] [Related]
60. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
Cilloni D; Messa F; Rosso V; Arruga F; Defilippi I; Carturan S; Catalano R; Pautasso M; Panuzzo C; Nicoli P; Messa E; Morotti A; Iacobucci I; Martinelli G; Bracco E; Saglio G
Leukemia; 2008 Jun; 22(6):1234-40. PubMed ID: 18401421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
